Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ese and other risks are described in greater detail in our Annual Report on Form 10-K for the year ended December 31, 2007, and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward looking statements because of these uncertainties, and the inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. We assume no obligation to update forward looking statements. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD -G

Table 1

Amicus Therapeutics, Inc.

(a development stage company)

Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

Period

from

February 4,

2002

(inception)

Three Months to

Ended March 31, March 31,

2007 2008 2008

Revenue:

Research revenue $- $2,466 $ 3,841

Collaboration revenue - 694 1,103

Total revenue - 3,160 4,944

Operating Expenses:

Research and development 7,085 6,941 96,819

General and administrative 2,850 5,186 43,256

Impairment
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 /PRNewswire-iReach/ -- Researchers found that ActiveLife Scientific,s ... with bone fragility fracture when today,s standard bone ... are at risk of fracture for reasons that ... test, the DEXA bone density scan.  Study results ... and Mineral Research Annual Conference (ASBMR) in ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
(Date:9/15/2014)... Sept. 15, 2014  FlexTech Alliance today issued ... printed product demonstrators (demos) and a functional electronic ... with pre-proposals due on October 22, 2014 and ... proposals ultimately selected are provided by the US ... cost share by the proposing organization. ...
(Date:9/15/2014)... NC (PRWEB) September 15, 2014 ... developed deep imaging OCT system for the optical device ... The EnvisuTM S4410 SDOCT for Contact Lens ... for standard and high complexity contact lens, IOL structures, ... imaging of a complete contact lens immersed in a ...
Breaking Biology Technology:ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2
... , , , ... ) announced that it will be hosting a conference call to discuss today,s ... begin at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT). , ... accessed through a link that is posted on the home page of Nektar,s ...
... ... firms have to follow a rigorous documentation process to comply with a ... corporate agreements these firms are faced with the daunting task of sharing ... affordable unlimited use facility to share thousands of confidential documents securely and ...
... question, researchers with the U.S. Department of Energy,s ... that the selective placement of strain can alter ... correlated electron materials. This unique class of materials ... display properties such as colossal magnetoresistance and high-temperature ...
Cached Biology Technology:Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119 2Life Science Firms are Turning to Firmex to do Deals Online 2Life Science Firms are Turning to Firmex to do Deals Online 3Strain on nanocrystals could yield colossal results 2Strain on nanocrystals could yield colossal results 3
(Date:9/15/2014)... gut microbes influence processes from digestion to disease resistance. ... biodiverse terrestrial ecosystems on the planet, more is known ... tropics. Smithsonian scientists and colleagues working on Panama,s Barro ... single tree were home to more than 400 different ... species contained more than 7,000 different kinds. , Bacteria ...
(Date:9/15/2014)... a morphine regimen can result in better pain control ... the dosage of the opioid needed to be effective, ... University. , The result could bring significant relief to ... felt in the arms and legs and associated with ... need for better treatments for neuropathic pain," said Fletcher ...
(Date:9/15/2014)... print issue of the journal Science comes ... Mexico, Montana and even the Netherlands, thanks to the ... the norm in these connected times. Yes, the research ... innovations in biology, medicine, biotechnology and agriculture. It could ... with that one, that one knew another one, and ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2Collaboration drives achievement in protein structure research 2
... early bird rates for the premier bone meeting in 2012. ... 21-24, 2012 will be held in in the magnificent city ... register by December 9, 2011 at http://www.iof-ecceo12.org ... key thought leaders... Plenary lectures:, The conundrum ...
... now possible to use dental X-rays to predict who is ... at the Sahlgrenska Academy reported in the journal Nature ... the University of Gothenburg,s Sahlgrenska Academy and Region Vstra Gtaland ... in the lower jaw is linked to a greater chance ...
... and more solar modules are appearing on rooftops, and ... into the grid. Multi-junction solar cells are particularly efficient ... to 43 percent - twice the level of conventional ... consist of several semi-conductor layers that combine to transform ...
Cached Biology News:Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux 2Dental X-rays can predict fractures 2Fraunhofer researchers receive the Franco-German Business Award 2011 2
... Dinitro-5,5'-dithiodibenzoic acid , DTNB , Ellman's reagent ... , *CAS-No.: 69-78-3 *Storage: ... with a reactive grouping not present in the ... reagent which will react directly with the product ...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... RNase Inhibitor (patent pending) is a protein ... binds and inhibits the most common and ... 1 and T1. SUPERaseIn can be used ... be problematic. It is ideal for in ...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
Biology Products: